Video by National Association of Investment Companies via YouTube
Source
After last year’s breakthrough mRNA-based COVID-19 vaccines by Pfizer-BioNTech and Moderna, there is much greater attention focused on companies behind the next wave of disruptive technologies, tools, and services leveraged by the biopharma industry.
In this NAIC Market Update, Daniella Kranjac, Founder of Dynamk Capital, shares her perspectives on the opportunities in life sciences industrials. These opportunities include novel cell, gene and mRNA therapies and other technologies the biopharma industry leverages for its essential work. Dynamk Capital is a growth equity and venture capital firm focused on life sciences industrials.